Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117946 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL1063199 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29384797 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31714182 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29358863 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL119588 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31369598 | 0.97 | MDM2 (0.53) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516252 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516240 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516235 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103789-A1 | METHOD FOR PREPARING LUTETIUM[177LU]DOTATATE AND PRECURSOR COMPOUND THEREOF | 迈得诺医疗科技集团有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-122036916-A | Ruitalu Process for producing peptide | 哈尔滨吉象隆生物技术有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | claimed |
| CN-121574188-A | Application of donkey-source bioactive peptide and its derivative in cosmetics | 上海湃肽生物科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250346559-A1 | COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION, KIT AND USE THEREOF | SIGNDO BIOTECHNOLOGY (SUZHOU) CO., LTD (CN) | 2025-11-13 | — | — | US | claimed |
| EP-4644369-A1 | COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION, KIT AND USE THEREOF | SIGNDO BIOTECHNOLOGY (SUZHOU) CO., LTD (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | SHANGHAI UNIVERSITY (CN) | 2025-10-23 | — | — | US | claimed |
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | SHILPA PHARMA LIFESCIENCES LIMITED (IN) | 2025-07-24 | — | — | US | claimed |
| WO-2025130972-A1 | SYNTHETIC METHOD FOR TIRZEPATIDE | 深圳翰宇药业股份有限公司 | 2025-06-26 | — | — | WO | claimed |
| CN-115215925-B | Somatostatin type 2 receptor inhibitor, radionuclide complex thereof, preparation method and application | 上海益泰医药科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-114249810-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114230637-A | Method for synthesizing deslorelin by solid and liquid | 湖南三太药业有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114181285-A | Method for synthesizing nafarelin by solid-liquid method | 湖南三太药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | Indian Institute of Technology Indore (IN) | 2022-02-24 | — | — | US | claimed |
| CN-114057862-A | Synthetic method of GLP-1(1-37) polypeptide | 安徽省国平药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114014912-A | Method for preparing leuprorelin by combining solid phase and liquid phase | 浙江湃肽生物有限公司南京分公司 | 2022-02-08 | — | — | CN | claimed |
| CN-113651875-B | Oligopeptide-34 synthesis method | 南京莱昂生物科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| EP-3941936-A2 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | Enzene Biosciences Ltd. (IN) | 2022-01-26 | — | — | EP | claimed |
| CN-113956333-A | Synthesis and purification method of linaclotide | 浙江湃肽生物有限公司南京分公司 | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, VIP | MDM4 1231/4885TP53 4366/4885MDM2 1541/4885 |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | STING1, CGAS, VIP | MDM4 1661/4885TP53 1709/4885MDM2 3166/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | MDM4 3864/4885TP53 4243/4885MDM2 2390/4885 |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | TEK, VIP, SCTR | MDM4 4645/4885TP53 2461/4885MDM2 4775/4885 |
| US-20250346559-A1 | COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION, KIT AND USE THEREOF | KIT, CD81, SLC7A1 | MDM4 3397/4885TP53 835/4885MDM2 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.